Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility
-- Ms. Jensen to oversee global CSR efforts and lead
“We are delighted to welcome Katharine to the Vertex family as we begin the next chapter in our efforts to give back to patients and the community,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “Her depth of experience in creating, launching and managing successful CSR programs, combined with her strong business acumen and passion for changing lives, makes her a tremendous addition to our team as we look to expand our corporate giving initiatives.”
“Vertex is deeply committed to patients, communities and stakeholders as
evidenced by its 10-year corporate giving commitment and creation of
Ms. Jensen is an accomplished executive with 15 years of international
CSR experience. Prior to joining Vertex, Ms. Jensen spent 10 years
leading global CSR efforts for
About Vertex
Vertex is a global biotechnology company that
invests in scientific innovation to create transformative medicines for
people with serious and life-threatening diseases. In addition to
clinical development programs in CF, Vertex has more than a dozen
ongoing research programs focused on the underlying mechanisms of other
serious diseases. Founded in 1989 in
For additional information and the latest updates from the company, please visit www.vrtx.com.
(VRTX-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20180910005534/en/
Source:
Vertex Pharmaceuticals Incorporated
Investors:
Michael
Partridge, +1 617-341-6108
or
Eric Rojas, +1 617-961-7205
or
Zach
Barber, +1 617-341-6470
or
Media:
Heather
Nichols, 617-341-6992
mediainfo@vrtx.com